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Aims To identify the genetic risk factors that influence the development of electrocardiographic (ECG) left ventricular
hypertrophy (LVH), a major risk factor for cardiovascular (CV) morbidity and mortality.
Methods
and results
We performed a genomewide association study (GWAS) of ECG-LVH, in which the community-based Korea Associ-
ation REsource (KARE) study (8432 controls and 398 cases) was analysed by Affymetrix SNP array 5.0. The GWAS
results were validated in hospital-based samples (597 controls and 207 cases). Fourteen single-nucleotide polymorph-
isms (SNPs) in eight genetic loci (5q35.1, 6p22.3-22.1, 8q24.2, 11p15, 11q21-22.1, 14q12, 17q11.2, and 19q13.1) were
associated with ECG-LVH in the original GWAS study (P, 1 × 1025). Of these SNPs, 12 were genotyped in the
hospital sample. There was consistent association with the 19q13.1 region which contains RYR1 gene. The most sig-
nificant SNP in the region was rs10500279, which had genomewide significance in the combined GWAS/replication
sample [odds ratio ¼ 1.58 (confidence interval: 1.35–1.85), P ¼ 1.0 × 1028]. Mutations in RYR1, which encodes a
major Ca2+ channel in the skeletal muscle, have been reported to correlate with CV diseases.
Conclusion We performed the first GWAS for ECG-LVH, implicating the skeletal muscle Ca2+ channel protein RYR1 as a genetic
risk factor. These results might increase our understanding of the development of ECG-LVH.
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Introduction
Left ventricular hypertrophy (LVH) is a major risk factor for cardio-
vascular (CV) morbidity and mortality. Left ventricular hypertrophy
is diagnosed by electrocardiography (ECG) and echocardiogra-
phy.1–4 Echocardiography is a more sensitive and specific method
of detecting LVH than ECG, but its use in large-scale population
studies and clinical trials is limited by its prohibitive cost and
operational considerations.5
In contrast, ECG is widely available, inexpensive, and less
operator-dependent6; thus, ECG data are obtainable in nearly all
patients and participants in epidemiological studies.7
Left ventricular hypertrophy is a multifactorial trait; its major
determinants include blood pressure (BP), age, gender, and
obesity.8 In addition, certain genetic factors, such as angiotensin-
converting enzyme,9 guanine nucleotide-binding protein
(GNB3),10 insulin-like growth factor,11 and neuropeptide Y,12
regulate the development of LVH. Several studies have reported
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a relationship between LVH and variations in genes that are associ-
ated with the renin–angiotensin–aldosterone system13,14 and
nitric oxide synthase.15
Recently, the EchoGen consortium (n ¼ 16 706 subjects of
European ancestry, based on five community cohorts) performed
a seminal genomewide association study (GWAS) on cardiac struc-
ture, based on echocardiography measurements.16 The GWAS
identified one locus (6q22) that correlated with LV diastolic dimen-
sions and four loci (5q23, 12p12, 12q14, and 17p13) that were
linked to the aortic root size.16 Its results, however, explained
merely 1–3% of the trait variance that was observed.16 Consider-
ing that the heritability estimate of LV mass ranges between 0.17
and 0.59, many genetic factors remain to be identified.17–20
Most studies that have sought to determine the genetic influence
on LVH have used echocardiography to measure LV mass. Yet, a
family study by Mayosi et al.7,21 estimated higher heritability rates
for LVH detected by ECG (ECG-LVH) (39–41%) compared with
LVH determined by echocardiography (ECHO-LVH) (21–29%),
suggesting that there may be greater genetic susceptibility for
ECG-LVH.
Here, we report the first GWAS on ECG-LVH using population-
based community cohorts and replicate the results in hospital-
based sample to identify genetic risk factors that influence the
development of ECG-LVH.
Methods
Original study subjects
The Korea Association REsource (KARE) subjects were described
previously.22 Briefly, the subjects came from two community-based
cohorts—the rural Ansung community and the urban Ansan
community—both located in KyungGi-Do province near Seoul, Korea.
Initially, there were 5018 and 5020 individuals, aged 40–70 years, from
Ansung and Ansan, respectively.
Subjects with genotype accuracies below 98% and high missing gen-
otype call rates (≥4%), high heterozygosity (.30%), or inconsistency
in sex were excluded from subsequent analyses. Individuals who had a
tumour were excluded, as were related individuals whose estimated
identity-by-state values were high (.0.80). After these quality
control steps, 8842 samples were selected, of whom 12 did not
undergo ECG. Ultimately, 8830 samples were used for the GWAS.
Left ventricular hypertrophy was diagnosed by ECG, based on the
Minnesota Code Classification System,23 if R amplitude is .26 mm
in V5 or V6; R amplitude .20 mm in leads I, II, or III; or aVF or R
amplitude .12 mm in the lead aVL (all criteria were measured on
the penultimate complete normal beat).
Blood pressure was measured three times in the supine position,
and the average value was used for the GWAS. Before the first
measurement, participants rested for 5 min, and the three measure-
ments were taken in one arm showing the higher BP at least 3 min
apart. Other CV risk factors, such as cholesterol level and fasting
glucose level, were measured from blood samples after overnight
fasting.
Original study genotypes
Most DNA samples were isolated from the peripheral blood of
participants and genotyped using the Affymetrix Genomewide
Human SNP array 5.0 (Affymetrix, Inc., Santa Clara, CA, USA). The
quality control steps of genotypes have been described elsewhere.22
Briefly, the accuracy of the genotyping was determined by Bayesian
Robust Linear Modeling using the Mahalanobis Distance (BRLMM) gen-
otyping algorithm.24 Consequently, 333 651 single-nucleotide poly-
morphisms (SNPs) had a missing genotype call rate below 0.1, a
minor allele frequency (MAF) .0.01, and no deviation from the
Hardy–Weinberg equilibrium (HWE) (P. 1 × 1026). To examine
the population stratification, multidimensional scaling analysis and prin-
cipal component analysis were performed using pruned 44 724 SNP
markers among all KARE.22
Replication study subjects
The replication study included 207 LVH patients and 597 normal con-
trols, selected from the patient database at the Cardiovascular
Genome Center, Yonsei University Health System, Seoul, Korea.
Both case and control subjects were independent from those of the
original GWAS study. The patient database comprises individuals
aged 40–70 years who entered the outpatient clinic or were hospital-
ized between May 2002 and November 2007 in the Cardiology Div-
ision of Severance Cardiovascular Hospital. Electrocardiographic-left
ventricular hypertrophy was diagnosed using the same criteria as in
the original GWAS—the Minnesota Code Classification System.23
The local Ethics Committee approved this study, and informed
consent was obtained from all patients.
Replication study genotypes
Single-nucleotide polymorphism selection for the replication study was
based on the significance with P-value (,1 × 1025). The SNPs were
genotyped by TaqManTM fluorogenic 5′ nuclease assay (Applied Biosys-
tems, Foster City, CA, USA). The final volume of each polymerase
chain reaction (PCR) was 5 mL, containing 5 ng genomic DNA,
2.5 mL TaqManTM Universal PCR Master Mix, and 0.13 mL 40× prede-
signed TaqMan probe Assay Mix.
The thermal cycling programme was as follows: 2 min at 508C to
activate uracil N-glycosylase and prevent contamination, 10 min at
958C to activate the DNA polymerase, and 45 cycles of 15 s at
958C and 1 min at 608C. All reactions were run in 384-well plates
on a Dual 384-Well GeneAmpw PCR System 9700 (Applied Biosys-
tems) and read on an ABI PRISM 7900 HT Sequence Detection
System (Applied Biosystems). Duplicate samples and negative controls
were included to ensure the accuracy of the genotyping data.
Statistical analysis
The ECG-LVH cases and controls were analysed by logistic regression,
controlling for covariates, such as antihypertensive drug treatment
state, cohort, age, sex, body mass index (BMI), systolic BP (SBP), dias-
tolic BP (DBP), and HDL, LDL, triglyceride, and fasting glucose levels.
Statistical analyses were performed using PLINK, version 1.07, using
default options25 and SPSS, v15.0. For the multicollinearity of covari-
ates, we estimated the tolerance and variance inflation factor (VIF)
by using the SPSS and described the results in Table 1. Multiple
testing of association results was conducted by the Bonferroni correc-
tion criteria. The asymptotic HWE tests were conducted using PLINK,
and all the reported P-values were two-sided.
Results
Baseline characteristics of subjects
Three hundred and ninety-eight individuals out of the 8830
community-based KARE subjects were diagnosed as ECG-LVH
by the Minnesota Code Classification System. The demographics
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and clinical characteristics of the subjects are shown in Table 1.
Antihypertensive treatment status, sex, age, BMI, SBP, DBP, and
LDL levels differed significantly between the case and control
groups of the KARE GWAS. Of the controls in the GWAS, 1217
(14%) subjects had taken antihypertensive medications compared
with 72 (17%) cases.
In the hospital-based replication study, antihypertensive treat-
ment status, age, HDL, LDL, and fasting glucose levels differed sig-
nificantly between the cases and controls. Ninety-nine (17%) of
controls had taken antihypertensive medications, as did 194
(95%) cases.
To avoid the multicollinearity of covariates, we tested the toler-
ance and VIF of them. The test results showed all VIF values lower
than 5, the suggested conservative threshold, suggesting the low
multicollinearities of covariates.26
Electrocardiographic-left ventricular
hypertrophy genomewide association
study
The ECG-LVH GWAS used KARE genotyped data previously
reported by Cho et al.22 A GWAS of 333 651 SNPs was performed
using community-based LVH cases (n ¼ 398) and controls
(n ¼ 8432); a quantile–quantile (Q–Q) plot is shown in Sup-
plementary material online, Figure S1A. The genomic inflation
factor (l) was 1.00, which was evidence against population strati-
fication or inflated results.
Figure 1A illustrates the Manhattan plot of the GWAS results; the
results that are based on P-values lower than 1 × 1025 are sum-
marized in Table 2. None of the P-values for the associations
met the multiple comparison criteria (Bonferroni’s correction
P, 1.5 × 1027). Therefore, instead of Bonferroni’s correction cri-
teria, a less stringent P-value (,1 × 1025) was applied to select
suggestive signals for further study in the replication sample.
The GWAS on ECG-LVH identified 14 SNPs in eight suggestive
association loci: one SNP in 5q35.1 (rs265992, P ¼ 1.2 × 1026),
one SNP in 6p22.3-22.1 (rs9295629, P ¼ 9.0 × 1026), five SNPs
in 8q24.2 (the most significant SNP: rs4909705, P ¼ 3.7 × 1026),
one SNP in 11p15 (rs17446021, P ¼ 4.9 × 1026), one SNP in
11q21-q22.1 (rs11225822, P ¼ 1.4 × 1026), one SNP in 14q12
(rs1956217, P ¼ 7.9 × 1026), one SNP in 17q11.2 (rs4239268,
P ¼ 9.9 × 1026), and three SNPs in 19q13.1 (the best SNP:
rs10500279, P ¼ 9.5 × 1027). The signal plots for each of
the eight loci are shown in Supplementary material online,
Figures S2–S9.
Validation in replication sample
Twelve of the 14 SNPs that we identified were genotyped in the
replication sample (207 cases and 597 controls). All genotypes
had low missing rate (0.1–3.2%) and none of SNPs failed to
meet the criteria of HWE. Of the 12 SNPs, 3 SNPs in RYR1, rya-
nodine receptor 1 (skeletal) in 19q13.1 were replicated at
P-values that ranged between 2.7 × 1022 and 3.6 × 1022 in
the hospital-based sample (Figure 2 and Table 2). Moreover,
the combined analysis of the KARE/replication sample demon-
strated that the association signals of all three SNPs passed the
threshold of significance for genomewide associations (P,
7.2 × 1028).26 The three SNPs lay in introns of RYR1 gene,
and rs10500279, the most significant SNP, had an odds ratio
(OR) of 1.58 [confidence interval (CI): 1.35–1.85] and P ¼
1.0 × 1028 (Figure 2 and Table 2).
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Table 1 Clinical characteristics of the KARE and replication study subjects
KARE subjects Case vs.
control,
P-valuea
Collinearity
statistics
Replication study
subjects
Case vs.
control,
P-valuea
Collinearity
statistics
Control Case Tolerance VIF Control Case Tolerance VIF
n 8432 398 597 207
Treatedb (%) 1217 (14) 72 (18) 4.3 × 1022 0.90 1.11 99 (17) 194 (95) 4.8 × 10243 0.77 1.30
Men (%) 3916 (46) 261 (66) 3.0 × 1028 0.90 1.11 430 (72) 161 (78) 2.5 × 1021 0.89 1.12
Mean (SD) Mean (SD)
Age 52.1 (8.9) 55.1 (9.2) 2.2 × 10211 0.81 1.24 57.4 (7.5) 58.3 (8.0) 1.2 × 1022 0.88 1.14
Body mass index 24.6 (3.1) 23.6 (2.9) 1.1 × 10211 0.80 1.24 24.2 (2.6) 24.5 (3.4) 3.0 × 1021 0.92 1.09
Systolic blood pressure (mmHg) 117.1 (18.0) 128.0 (20.8) 1.7 × 10231 0.29 3.41 124.3 (17.9) 126.9 (21.0) 2.7 × 1021 0.42 2.35
Diastolic blood pressure
(mmHg)
74.9 (11.5) 79.4 (11.7) 1.6 × 10214 0.32 3.08 78.4 (10.9) 77.6 (11.2) 2.6 × 1021 0.43 2.34
HDL cholesterol (mg/dL) 44.6 (10.1) 45.3 (10.6) 1.7 × 1021 0.80 1.25 48.9 (15.2) 44.0 (12.9) 9.7 × 1029 0.90 1.11
LDL cholesterol (mg/dL) 116.0 (32.2) 110.3 (32.7) 6.8 × 1024 0.93 1.07 120.1 (35.3) 97.0 (33.7) 1.2 × 1022 0.87 1.15
Triglyceride (mg/dL) 163.0 (106.1) 162.6 (98.6) 9.4 × 1021 0.77 1.30 140.8 (95.0) 135.1 (103.0) 5.6 × 1021 0.91 1.10
Fasting glucose level (mg/dL) 87.7 (22.0) 86.9 (19.4) 4.8 × 1021 0.94 1.06 96.1 (27.4) 114.1 (52.1) 1.6 × 1026 0.84 1.20
SD, standard deviation; VIF, variance inflation factor.
aP-values between control and case were calculated using x2 for treated and sex ratio, and Student’s t-test for quantitative traits.
bAntihypertensive drug-treated subjects.
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Discussion
In this GWAS of ECG-LVH using community-based cohorts, three
SNPs in RYR1 in the 19q13.1 locus approached significance; these
were replicated in a hospital-based cohort. This GWAS of
ECG-LVH contributes to the existing body of literature, which,
until now, has focused on ECHO-LVH; studies on the ECG
indices reflective of LVH may reflect disparate biological processes
compared with anatomical measures by echocardiography.7
A report on the genomewide linkage of ECG-LVH by Mayosi
et al.21 identified three suggestive loci: 10q23 for Sokolow–Lyon
voltage, 17p13.3 for Cornell voltage product, and 12q14.1 for
ECG LV mass. As shown in Figure 1B, no loci overlapped
between this report and our findings, which might be attributed
to disparate methods of establishing the LVH criteria (we used
the Minnesota Code Classification System)23 and differences in
the power of detection between linkage studies and GWASs.27
In addition, it was difficult to identify LVH-associated loci that over-
lapped between the EchoGen GWAS16 and this study, which might
reflect the disparate biologies of ECG-LVH and ECHO-LVH.
Several limitations should be addressed with regard to the
interpretation of our results. In this study, only Minnesota ECG
criteria were used to diagnose ECG-LVH cases. However,
Hsieh et al.28 suggested that compared with voltage-only criteria
for detecting LVH, composite ECG criteria were more strongly
predictive of CV mortality. Further, ECG voltage criteria detect
LV wall thickness indirectly. Second, because the sample size of
the replication study was not large, we could not rule out the
possibility that other suggestive loci, such as DRD1, a known
CV risk factor, are associated with ECG-LVH.29 To confirm
other suggestive loci, they must be examined in a larger associ-
ation study.
RYR1 has been well studied with regard to muscle contraction.
Regulated increases in intracellular Ca2+ are required for many
physiological functions, including muscle contraction, secretion,
regulation of gene expression, and fertilization.30 Intracellular
Ca2+ can be elevated via activation of plasma membrane-bound
Ca2+-permeable channels or the release of Ca2+ from intracellular
stores.31 The rise in Ca2+ that is required for myocyte contraction
is affected by the activation of RYRs, sarcoplasmic reticulum-bound
Ca2+ release channels.32
Over the past 20 years, several mutations in RYR1 and RYR2 have
been identified and linked to skeletal and cardiac diseases.33 Malig-
nant hyperthermia,34 central core disease,34 and catecholaminergic
polymorphic ventricular tachycardia35,36 have been associated
genetically with mutations in RYR1 or RYR2. Further, several
reports in animal models have demonstrated the involvement of
RYRs in alterations in LVH, which observed that the density of
RYRs decreased in hypertrophied rat hearts, resulting in impaired
calcium flux,37 and that RYRs were distributed transmurally during
LVH in dogs.38
Based on previous functional studies and the results observed
in this study, it would be reasonable to speculate that RYRs are
associated with LVH. It is difficult, however, to understand why
RYR1, the predominant isoform in the skeletal muscle, has a
stronger association with LVH than RYR2, the major isoform in
the cardiac muscle [best SNP: rs3766884, OR ¼ 0.81 (CI: 0.69–
0.94), P ¼ 0.006]. It is possible that RYR1 or its genetic variants
have stronger influence on LVH compared with that of RYR2.
Otherwise, RYR1 expression in the vascular smooth muscle
Figure 1 Manhattan plot for the electrocardiographic-left ventricular hypertrophy GWAS and the names of genes with P-values lower than
1 × 1025 (A). Previously reported left ventricular hypertrophy candidate loci by the EchoGen genomewide association study16 and a genome-
wide linkage study21 (B).
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Table 2 Logistic regression analysis results of the original genomewide association study and replication study, controlling for antihypertensive drug-treated
states, cohort, age, sex, and cardiovascular risk factorsa as covariates
Chr rsID Position Locus Proximal gene M KARE GWAS (cases 398/controls
8432)
Replication study (cases 207/controls
597)
Combined analysis (cases
605/controls 9029)
MAF OR L95 U95 P-value MAF OR L95 U95 P-value OR L95 U95 P-value
5 rs265992 174846655 5q35.1 DRD1 A 0.1 1.70 1.37 2.10 1.2E206 0.088 0.76 0.39 1.48 4.2E201 1.46 1.20 1.78 1.6E204
6 rs9295629 24654266 6p22.3-22.1 TTRAP T 0.039 1.99 1.47 2.71 9.0E206 0.037 0.61 0.17 2.13 4.4E201 1.62 1.21 2.18 1.2E203
8 rs6577840 138805432 8q24.2 FAM135B C 0.159 1.52 1.27 1.83 7.1E206 0.153 0.94 0.59 1.51 8.1E201 1.38 1.18 1.63 9.2E205
8 rs4909705 138805788 8q24.2 FAM135B T 0.16 1.54 1.28 1.85 3.7E206 0.149 1.00 1.00 1.01 7.7E201 1.42 1.20 1.67 2.6E205
8 rs7825068 138807660 8q24.2 FAM135B T 0.159 1.53 1.28 1.84 5.0E206 0.154 0.94 0.58 1.50 7.8E201 1.39 1.18 1.63 8.0E205
8 rs7840530 138811480 8q24.2 FAM135B A 0.162 1.51 1.26 1.81 7.3E206 0.153 0.93 0.58 1.51 7.8E201 1.38 1.17 1.62 9.6E205
11 rs17446021 11761070 11p15 GALNTL4 A 0.014 2.81 1.80 4.37 4.9E206 0.011 5.63 0.74 42.88 9.5E202 2.26 1.47 3.48 2.2E204
11 rs11225822 103345030 11q21-q22.1 DYNC2H1 C 0.087 1.71 1.38 2.13 1.4E206 0.091 1.35 0.74 2.48 3.3E201 1.62 1.33 1.97 1.2E206
17 rs4239268 40154777 17q11.2 DNAJC7 C 0.15 1.52 1.26 1.82 9.9E206 0.131 0.86 0.51 1.46 5.8E201 1.38 1.17 1.63 1.5E204
19 rs2071090 39015454 19q13.1 RYR1 G 0.219 1.49 1.26 1.76 2.2E206 0.236 1.59 1.05 2.41 2.7E202 1.49 1.30 1.72 3.6E208
19 rs10500279 39035068 19q13.1 RYR1 G 0.157 1.57 1.31 1.88 9.5E207 0.173 1.65 1.03 2.65 3.6E202 1.58 1.35 1.85 1.0E208
19 rs2960321 39048163 19q13.1 RYR1 A 0.212 1.49 1.27 1.76 2.0E206 0.232 1.59 1.04 2.42 3.1E202 1.50 1.30 1.73 2.5E208
Chr, chromosome; rsID, SNP ID in dbSNP database; BP, base position, based on the latest genome version (hg19); MAF, minor allele frequency; M, minor allele; OR, odds ratio; L95 and U95, confidence interval lower and upper 95%,
respectively.
aThe cardiovascular risk factors are BMI, SBP, DBP, HDL, LDL, TG, and fasting glucose level.
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(rather than cardiac muscle) might regulate BP and affect
ECG-LVH secondarily. To examine this possibility, we performed
an association analysis of RYR1 SNPs with SBP and DBP.
However, there was no association found in this analysis, indicating
that this possibility is low (data not shown).
Therefore, to better understand the mechanism responsible for
the potential association between RYR1 and ECG-LVH, further
examination through functional analysis of RYRs is necessary.
In conclusion, we have reported the first GWAS of ECG-LVH,
with which variations in RYR1 were associated and this finding
will increase our understanding of the aetiology of ECG-LVH.
Supplementary material
Supplementary material is available at European Heart Journal
online.
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